Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.76 |
| ▸ | ITGAV | P06756 | 15/20 | 0.76 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.73 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.71 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.67 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31294830 | 0.93 | ITGB3 (0.80) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| Cyclorgdfv SCHEMBL30636069 | 0.91 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| Cyclorgdfv SCHEMBL29384091 | 0.91 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL29464836 | 0.90 | ITGB3 (0.75) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL29578997 | 0.90 | ITGB3 (0.75) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL29366713 | 0.89 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| SCHEMBL17364341 | 0.89 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| Cilengitide SCHEMBL34082 | 0.86 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| Cilengitide SCHEMBL19534260 | 0.86 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGA5 | |
| Cilengitide SCHEMBL26970603 | 0.86 | ITGB3 (0.78) | ITGB3ITGAVITGB5ITGA2BITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024434-A1 | Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles | SOMALOGIC, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024434-A1 | Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles | TTR, TPX2, FABP1 | ITGB3 2444/4885ITGAV 1301/4885ITGB5 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.